Kircheis et al., 2021 - Google Patents
COVID-19: Mechanistic model of the african paradox supports the central role of the NF-κB pathwayKircheis et al., 2021
View HTML- Document ID
- 6421655939244346759
- Author
- Kircheis R
- Schuster M
- Planz O
- Publication year
- Publication venue
- Viruses
External Links
Snippet
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has expanded into a global pandemic, with more than 220 million affected persons and almost 4.6 million deaths by 8 September 2021. In particular, Europe and the Americas have been heavily …
- 102000003945 NF-kappa B 0 title abstract description 84
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lynch et al. | Role of senescence and aging in SARS-CoV-2 infection and COVID-19 disease | |
| Kircheis et al. | COVID-19: Mechanistic model of the african paradox supports the central role of the NF-κB pathway | |
| Abu-Hammad et al. | Factors influencing global variations in COVID-19 cases and fatalities; a review | |
| Chang et al. | Anti-apoptotic and pro-survival effect of alpinate oxyphyllae fructus (AOF) in a d-galactose-induced aging heart | |
| Yang et al. | Green tea polyphenol catechins inhibit coronavirus replication and potentiate the adaptive immunity and autophagy-dependent protective mechanism to improve acute lung injury in mice | |
| Akinosoglou et al. | Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: A comprehensive review of clinical experience | |
| Heiat et al. | Integrative role of traditional and modern technologies to combat COVID-19 | |
| Kim | Viral infection and airway epithelial immunity in asthma | |
| Rzymski et al. | Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review | |
| Shende et al. | Drug repurposing: new strategies for addressing COVID-19 outbreak | |
| Chen et al. | Novel antiviral strategies in the treatment of COVID-19: a review | |
| Haddad et al. | A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19 | |
| Banerjee et al. | Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits | |
| Ting et al. | SARS-CoV-2: Overview and its impact on oral health | |
| Arora et al. | Vitamin D and the ability to produce 1, 25 (OH) 2D are critical for protection from viral infection of the lungs | |
| Ramasamy | Perspective of the relationship between the susceptibility to initial SARS-CoV-2 infectivity and optimal nasal conditioning of inhaled air | |
| Shin et al. | Towards goals to refine prophylactic and therapeutic strategies against COVID-19 linked to aging and metabolic syndrome | |
| Khamees et al. | SARS-CoV-2 and coronavirus disease mitigation: treatment options, vaccinations and variants | |
| Rao et al. | An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19 | |
| Lauro et al. | Could antigen presenting cells represent a protective element during sars-cov-2 infection in children? | |
| Dmytrenko et al. | Cardiovascular tropism and sequelae of SARS-CoV-2 infection | |
| Sarker et al. | A comprehensive overview of the newly emerged COVID-19 pandemic: features, origin, genomics, epidemiology, treatment, and prevention | |
| Casetti et al. | COVID-19 in patients with hematologic diseases | |
| Zeng et al. | Levistolide A inhibits PEDV replication via inducing ROS generation | |
| Tellez et al. | Analysis of COVID-19 on diagnosis, vaccine, treatment, and pathogenesis with clinical scenarios |